Tech Transfer eNews Blog

Cold Spring Harbor Lab partners with Autobahn Labs to bring more therapeutics to market

By Jesse Schwartz
Published: June 9th, 2021

Cold Spring Harbor Laboratory (CSHL) is partnering with life science incubator Autobahn Labs to launch more start-ups to take new therapeutics from the lab to the marketplace.

With support from life science investment firm Samsara BioCapital and global drug discovery firm Evotec SE, Autobahn will provide investments of up to $5 million for early-stage drug discovery projects at CSHL that are beyond the academic funding model.

The investments will help create jointly owned start-ups, provide business and research expertise to guide drug development, and provide access to Evoctec’s drug discovery and development platforms. Autobahn has the option to license successful technology from CSHL and move a company forward for a traditional Series A round of funding led by Samsara BioCapital.

“CSHL welcomes Autobahn’s innovative funding model as part of our high-value business development strategies for early-stage translational opportunities,” says Andrew Whiteley, vice president of business development and tech transfer at CSHL.

“Autobahn has the ability to get involved early, put their resources into CSHL’s drug discovery programs, and generate a pipeline of highly investable spin-out companies,” adds Whiteley. “This collaboration will enable us to advance our basic biology expertise more quickly from the lab to the clinic.”

Thomas Novak, chief scientific officer at Autobahn, comments, “Autobahn is honored to work with CSHL’s world-leading scientists to identify promising innovations for advancement from target discovery to preclinical drug candidates. This collaboration provides CSHL with the resources to confirm the viability of promising therapies early and accelerate those with the highest therapeutic potential.”

Source: Cold Spring Harbor Laboratory

Posted under: Tech Transfer e-News